Drug intelligence / Profile preview

caffeine + glucosyl hesperidin

Development stage: Unknown
Lead developer: House Foods
Modality: Small Molecules
Administration: Oral

Overview

A combination of caffeine and glucosyl hesperidin (G-hesperidin) that has demonstrated anti-obesity effects. This combination works primarily by inhibiting hepatic lipogenesis (fat formation in the liver) and reducing subcutaneous abdominal fat. Clinical studies have shown that 500 mg of glucosyl hesperidin combined with 50-75 mg of caffeine can significantly reduce body fat and body mass index (BMI) in moderately obese subjects.

Beyond the preview

Go deeper on caffeine + glucosyl hesperidin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on caffeine + glucosyl hesperidin.

Explore the full profile